HIV-1 Viral Load and Other Risk Factors for Mother-to-Child Transmission of HIV-1 in a Breast-Feeding Population in Cote d'Ivoire

Denise J. Jamieson, Toussaint S. Sibailly, Ramses F Sadek, Thierry H. Roels, Ehounou R. Ekpini, Edith Boni-Ouattara, John M. Karon, John Nkengasong, Alan E. Greenberg, Stefan Z. Wiktor

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Short-course antiretroviral regimens have been evaluated to reduce mother-to-child transmission of HIV in resource-limited settings. This report from Abidjan, Cote d'Ivoire, examines the risk factors for HIV transmission by 1 and 24 months among breastfeeding women. Eligible HIV-1-seropositive pregnant women enrolled in this randomized double-blind clinical trial were randomly assigned to receive either oral zidovudine (ZDV) (n = 126) prophylaxis or placebo (n = 124). Maternal prophylaxis began at 36 weeks of gestation (300 mg ZDV twice daily antepartum and 300 mg every 3 hours intrapartum); there was no neonatal prophylaxis component. The cumulative risk of transmission in the treatment group was 11.9% and 22.1% by 1 and 24 months, respectively. In adjusted analyses, viral load at enrollment was the strongest predictor of transmission (per log increment: odds ratio [OR] = 4.8, 95% confidence interval [CI]: 2.5-9.5 at 1 month; OR = 5.7; 95% CI: 3.1-10.8 at 24 months). Overall, ZDV prophylaxis was not significantly protective for infection at 1 or 24 months. Comparing ZDV with placebo following dichotomization of viral load (<50,000 vs. ≥50,000 copies/mL) at enrollment, however, there was a significant effect of ZDV seen only among those women with a low viral load at enrollment. The substantial risk of transmission despite ZDV prophylaxis, particularly among those with higher viral loads, underscores the need to find more effective regimens appropriate for use in resource-limited settings.

Original languageEnglish (US)
Pages (from-to)430-436
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume34
Issue number4
DOIs
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Cote d'Ivoire
Zidovudine
Breast Feeding
Viral Load
HIV-1
Mothers
Population
Odds Ratio
Placebos
Confidence Intervals
Pregnant Women
Clinical Trials
HIV
Pregnancy
Infection

Keywords

  • Perinatal HIV clinical trial

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

HIV-1 Viral Load and Other Risk Factors for Mother-to-Child Transmission of HIV-1 in a Breast-Feeding Population in Cote d'Ivoire. / Jamieson, Denise J.; Sibailly, Toussaint S.; Sadek, Ramses F; Roels, Thierry H.; Ekpini, Ehounou R.; Boni-Ouattara, Edith; Karon, John M.; Nkengasong, John; Greenberg, Alan E.; Wiktor, Stefan Z.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 34, No. 4, 01.12.2003, p. 430-436.

Research output: Contribution to journalArticle

Jamieson, DJ, Sibailly, TS, Sadek, RF, Roels, TH, Ekpini, ER, Boni-Ouattara, E, Karon, JM, Nkengasong, J, Greenberg, AE & Wiktor, SZ 2003, 'HIV-1 Viral Load and Other Risk Factors for Mother-to-Child Transmission of HIV-1 in a Breast-Feeding Population in Cote d'Ivoire', Journal of Acquired Immune Deficiency Syndromes, vol. 34, no. 4, pp. 430-436. https://doi.org/10.1097/00126334-200312010-00011
Jamieson, Denise J. ; Sibailly, Toussaint S. ; Sadek, Ramses F ; Roels, Thierry H. ; Ekpini, Ehounou R. ; Boni-Ouattara, Edith ; Karon, John M. ; Nkengasong, John ; Greenberg, Alan E. ; Wiktor, Stefan Z. / HIV-1 Viral Load and Other Risk Factors for Mother-to-Child Transmission of HIV-1 in a Breast-Feeding Population in Cote d'Ivoire. In: Journal of Acquired Immune Deficiency Syndromes. 2003 ; Vol. 34, No. 4. pp. 430-436.
@article{1b407a92099d4d6284f2e33e6a7703b6,
title = "HIV-1 Viral Load and Other Risk Factors for Mother-to-Child Transmission of HIV-1 in a Breast-Feeding Population in Cote d'Ivoire",
abstract = "Short-course antiretroviral regimens have been evaluated to reduce mother-to-child transmission of HIV in resource-limited settings. This report from Abidjan, Cote d'Ivoire, examines the risk factors for HIV transmission by 1 and 24 months among breastfeeding women. Eligible HIV-1-seropositive pregnant women enrolled in this randomized double-blind clinical trial were randomly assigned to receive either oral zidovudine (ZDV) (n = 126) prophylaxis or placebo (n = 124). Maternal prophylaxis began at 36 weeks of gestation (300 mg ZDV twice daily antepartum and 300 mg every 3 hours intrapartum); there was no neonatal prophylaxis component. The cumulative risk of transmission in the treatment group was 11.9{\%} and 22.1{\%} by 1 and 24 months, respectively. In adjusted analyses, viral load at enrollment was the strongest predictor of transmission (per log increment: odds ratio [OR] = 4.8, 95{\%} confidence interval [CI]: 2.5-9.5 at 1 month; OR = 5.7; 95{\%} CI: 3.1-10.8 at 24 months). Overall, ZDV prophylaxis was not significantly protective for infection at 1 or 24 months. Comparing ZDV with placebo following dichotomization of viral load (<50,000 vs. ≥50,000 copies/mL) at enrollment, however, there was a significant effect of ZDV seen only among those women with a low viral load at enrollment. The substantial risk of transmission despite ZDV prophylaxis, particularly among those with higher viral loads, underscores the need to find more effective regimens appropriate for use in resource-limited settings.",
keywords = "Perinatal HIV clinical trial",
author = "Jamieson, {Denise J.} and Sibailly, {Toussaint S.} and Sadek, {Ramses F} and Roels, {Thierry H.} and Ekpini, {Ehounou R.} and Edith Boni-Ouattara and Karon, {John M.} and John Nkengasong and Greenberg, {Alan E.} and Wiktor, {Stefan Z.}",
year = "2003",
month = "12",
day = "1",
doi = "10.1097/00126334-200312010-00011",
language = "English (US)",
volume = "34",
pages = "430--436",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - HIV-1 Viral Load and Other Risk Factors for Mother-to-Child Transmission of HIV-1 in a Breast-Feeding Population in Cote d'Ivoire

AU - Jamieson, Denise J.

AU - Sibailly, Toussaint S.

AU - Sadek, Ramses F

AU - Roels, Thierry H.

AU - Ekpini, Ehounou R.

AU - Boni-Ouattara, Edith

AU - Karon, John M.

AU - Nkengasong, John

AU - Greenberg, Alan E.

AU - Wiktor, Stefan Z.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Short-course antiretroviral regimens have been evaluated to reduce mother-to-child transmission of HIV in resource-limited settings. This report from Abidjan, Cote d'Ivoire, examines the risk factors for HIV transmission by 1 and 24 months among breastfeeding women. Eligible HIV-1-seropositive pregnant women enrolled in this randomized double-blind clinical trial were randomly assigned to receive either oral zidovudine (ZDV) (n = 126) prophylaxis or placebo (n = 124). Maternal prophylaxis began at 36 weeks of gestation (300 mg ZDV twice daily antepartum and 300 mg every 3 hours intrapartum); there was no neonatal prophylaxis component. The cumulative risk of transmission in the treatment group was 11.9% and 22.1% by 1 and 24 months, respectively. In adjusted analyses, viral load at enrollment was the strongest predictor of transmission (per log increment: odds ratio [OR] = 4.8, 95% confidence interval [CI]: 2.5-9.5 at 1 month; OR = 5.7; 95% CI: 3.1-10.8 at 24 months). Overall, ZDV prophylaxis was not significantly protective for infection at 1 or 24 months. Comparing ZDV with placebo following dichotomization of viral load (<50,000 vs. ≥50,000 copies/mL) at enrollment, however, there was a significant effect of ZDV seen only among those women with a low viral load at enrollment. The substantial risk of transmission despite ZDV prophylaxis, particularly among those with higher viral loads, underscores the need to find more effective regimens appropriate for use in resource-limited settings.

AB - Short-course antiretroviral regimens have been evaluated to reduce mother-to-child transmission of HIV in resource-limited settings. This report from Abidjan, Cote d'Ivoire, examines the risk factors for HIV transmission by 1 and 24 months among breastfeeding women. Eligible HIV-1-seropositive pregnant women enrolled in this randomized double-blind clinical trial were randomly assigned to receive either oral zidovudine (ZDV) (n = 126) prophylaxis or placebo (n = 124). Maternal prophylaxis began at 36 weeks of gestation (300 mg ZDV twice daily antepartum and 300 mg every 3 hours intrapartum); there was no neonatal prophylaxis component. The cumulative risk of transmission in the treatment group was 11.9% and 22.1% by 1 and 24 months, respectively. In adjusted analyses, viral load at enrollment was the strongest predictor of transmission (per log increment: odds ratio [OR] = 4.8, 95% confidence interval [CI]: 2.5-9.5 at 1 month; OR = 5.7; 95% CI: 3.1-10.8 at 24 months). Overall, ZDV prophylaxis was not significantly protective for infection at 1 or 24 months. Comparing ZDV with placebo following dichotomization of viral load (<50,000 vs. ≥50,000 copies/mL) at enrollment, however, there was a significant effect of ZDV seen only among those women with a low viral load at enrollment. The substantial risk of transmission despite ZDV prophylaxis, particularly among those with higher viral loads, underscores the need to find more effective regimens appropriate for use in resource-limited settings.

KW - Perinatal HIV clinical trial

UR - http://www.scopus.com/inward/record.url?scp=0345256368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345256368&partnerID=8YFLogxK

U2 - 10.1097/00126334-200312010-00011

DO - 10.1097/00126334-200312010-00011

M3 - Article

C2 - 14615662

AN - SCOPUS:0345256368

VL - 34

SP - 430

EP - 436

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -